Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk

Prostate

Volumn 64, Issue 3, 2005, Pages 240-245

  Berger, Andreas P ^a   Deibl, Martina ^b   Steiner, Hannes ^a   Bektic, Jasmin ^a   Pelzer, Alexandre ^a   Spranger, Robert ^a   Klocker, Helmut ^a   Bartsch, Georg ^a   Horninger, Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Benign prostatic hyperplasia; Prostate cancer; PSA doubling time; PSA velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY;

ADULT; AGED; BIOPSY; HUMANS; LONGITUDINAL STUDIES; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; RISK FACTORS;

EID: 22144445291     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20210     Document Type: Article

References (20)

1. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: Prostate and endometrial cancers. CA Cancer J Clin 1993;43:42-46.
2. Labrie F, Dupont A, Suburu R, Cusan L, Trenblay M, Gomez JL, Emond J. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992;147:846-852.
3. Labrie F, Candas B, Cusan L, Gomez J, Diamond P, Suburu R, Lemay M. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996;47:212-217.
4. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong ENP, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 1998;279:1542-1547.
5. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves. J Urol 1994;152:2037-2042.
6. DeKoning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, Gohagan JK, Hakama M, Hugosson J, Kranse R, Nelen V, Prorok PC, Schroeder FH. Large-scale randomized prostate cancer trials: Program performances in the European Randomized Screening for Prostate Cancer Trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002;97:237-244.
7. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate specific antigen in a community-based population of healthy men: Establishment of age specific reference ranges. JAMA 1993;270:860-864.
8. Reissigl A, Horninger W, Fink K, Klocker H, Bartsch G. Prostate carcinoma screening in the federal state of Tyrol, Austria. Cancer 1997;80:1818-1829.
9. Schroeder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000;163:806-812.
10. Roobol MJ, Kranse R, deKoning HJ, Schroeder FH. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: Results of second screening round or ERSPC (Rotterdam). Urology 2004;63:309-314.
11. Berger AP, Spranger R, Kofler K, Steiner H, Bartsch G, Horninger W. Early detection of prostate cancer with low psa cut-off values leads to significant stage migration in radical prostatectomy specimens. Prostate 2003;57:93-98.
12. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997;277:1456-1460.
13. Freedland SJ, Mangold LA, Epstein JI, Partin AW. Biopsy indication-A predictor of pathologic stage among men with preoperative serum psa levels of 4.0 ng/ml or less and T1c disease. Urology 2004;63:887-891.
14. Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WJ, Babaian RJ. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/ml. J Urol 2001;165:1930-1936.
15. Horninger W, Volgger H, Rogatsch H, Gschwendtner A, Bartsch G. Consideration of low psa cut-off levels to optimize the detection of curable prostate cancer. Eur Urol 2001;39:43-46.
16. Fang J, Metter EJ, Landis P, Carter HB. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 2002;59:889-894.
17. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh P. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-2220.
18. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA. Prevalence of prostate cancer among men with a prostate-specific antigen level <4 ng per milliliter. N Engl J Med 2004;350:2239-2246.
19. Morgan TO, Jacobsen SJ, McCarthy WF, McLeod DG, Moul JW. Age-specific reference ranges for prostate-specific antigen-based detection of prostate cancer in African-American men. N Eng J Med 1996;335:304-310.
20. Moul JW. PSA thresholds for prostate cancer detection. JAMA 1997;278:699.